Health Care·Biotechnology·$79.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.45 | N/A | -23.47% |
management commentary, guidance changes, and full analysis available with Pro.
| -23.47% |
Tone: Defensive
Management expressed concerns about current market conditions impacting earnings. They remain committed to long-term growth through research and development.
Management acknowledged the challenges faced in the quarter.
They emphasized ongoing investments in R&D despite the EPS miss.
The earnings report indicates that Regeneron Pharmaceuticals faced challenges this quarter, resulting in a significant EPS miss. The stock reacted negatively, dropping 6.34%. Investors are likely concerned about the company's ability to meet future earnings expectations without updated guidance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERICAN INTL GROUP
May 6, 2019